In vitro combination of Gamitrinib with c-Myc inhibitors, such as OTX015, or with c-Myc silencing impairs proliferation of GSCs and promotes apoptosis, while, in vivo, Gamitrinib mediates tumor regression through enhanced cell death and decreased cell proliferation [117]. The gene discussed is MYC; the disease is neoplasm.